Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference

Abstract

Peritoneal mesothelioma is a rare cancer of the peritoneum with about 250 new cases diagnosed each year in the United States. It is the second most common site for mesothelioma development and accounts for 10-20% of all mesotheliomas diagnosed in the United States. A meeting sponsored by the NIH Office of Rare Diseases was held in Bethesda, Maryland on September 13 and 14, 2004. The objective of this meeting was to review the epidemiology, biology and current surgical and medical management of peritoneal mesothelioma. In addition, the meeting also discussed clinical and pre-clinical evaluation of novel treatments for mesothelioma as well as ongoing laboratory research to better understand this disease. This report summarizes the proceedings of the meeting as well as directions for future clinical and basic research.

Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview

“…This literature includes a systematic review and a meta-analysis [30,31]. A multidisciplinary conference in 2006 at the National Institutes of Health sponsored by the National Organization for Rare Diseases concluded that CRS plus perioperative chemotherapy may be considered by the multidisciplinary team as an initial treatment plan for patients with MPM [32]. The Peritoneal Surface Oncology Group International (PSOGI) consensus conference in 2008 declared CRS and perioperative chemotherapy as the standard of care for this disease realizing that knowledgeable selection of patients for such an aggressive treatment plan is necessary [33].…”

Why RECIST Works and Why It Should Stay—Counterpoint

“…Not all cancers behave equally, and how drugs kill cancer cells varies greatly. We may need to make adjustments for some cancers such as gastrointestinal stromal tumor (GIST) or mesothelioma (8)(9)(10)(11). In GIST, for example, investigators incorporated tumor density on computed tomographic (CT) scan and one-dimensional measurement of tumor lesions in their assessment of a population of patients who were divided into good and poor responders by the criterion of a decrease in standardized uptake value (SUV) of <2.5 measured by 2[18F]fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET).…”

Laparoscopy and Well-Differentiated Papillary Mesothelioma of the Peritoneum

“…Other findings include ascites, infiltrating mass involving the serous of the bowels, direct invasion within the liver, spleen and abdominal wall, retroperitoneal adenopathies and metastasis at distance. 30 The pelvic involvement can suitably be evaluated by ultrasound as well as a small amount of liquid at cul-de-sac. 19 Few data has been published about the magnetic resonance imaging and PET-CT imaging manifestations.…”